Trial abstract · §3
SURPASS-CVOT — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Time to first major adverse cardiovascular event, tirzepatide versus dulaglutide | Non-inferior to dulaglutide on the primary composite. The Institute records that an active-controlled non-inferiority design cannot establish superiority over placebo and does not report it as though it had | Moderate |
| Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed. | ||
§3.2Endpoint hierarchy
Table 4. Relative and absolute effect. The Institute reports both, because a relative measure without a baseline risk cannot be acted on and systematically overstates benefit in lower-risk populations.
| Measure | Value | Note |
|---|---|---|
| Hazard ratio as reported | 0.85 | Reproduced from the published report. |
| Comparator event rate, % | 10.9 | Illustrative. A rate typical of the enrolled risk profile, used to convert the relative measure. Not a published figure. |
| Absolute risk difference, pp | 1.64 | Illustrative. Computed from the two rows above. |
| Number needed to treat | 61 | Illustrative. For the stated duration, at the comparator rate assumed above. Rises sharply as baseline risk falls. |
| Three of the four rows are Institute constructions and are marked. Only the hazard ratio is a published figure. | ||
§3.3Harms as reported
Table 5. Adverse events for Tirzepatide from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Nausea | 29.0 | 9.5 | SURMOUNT-1 (15 mg, 72 weeks) |
| Diarrhoea | 23.4 | 7.3 | SURMOUNT-1 |
| Constipation | 11.7 | 5.8 | SURMOUNT-1 |
| Vomiting | 12.8 | 2.6 | SURMOUNT-1 |
| Dyspepsia | 9.1 | 2.9 | SURMOUNT-1 |
| Injection-site reaction | 5.6 | 0.9 | SURMOUNT-1 |
| Alopecia | 5.4 | 1.0 | SURMOUNT-1 |
| Cholelithiasis | 1.6 | 0.4 | SURMOUNT-1 |
Compound Evidence Institute · CEI-TR-0034/3 · https://compoundevidence.com/trials/surpass-cvot/results/ · retrieved 30 July 2026